ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$597M
(+20%)
Cap. Flow
+$37.8M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
76
Reduced
73
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Korro Bio
KRRO
$245M
| $1.65M | 0.27% |
49,451
+42,241
| +586% | +$1.41M |
|
52
Aldeyra Therapeutics
ALDX
$350M
| $1.63M | 0.26% |
+302,212
| New | +$1.63M |
|
53
Instil Bio
TIL
$196M
| $1.6M | 0.26% |
+23,707
| New | +$1.6M |
|
|
AACT
54
Ares Acquisition Corporation II
AACT
$706M
| $1.51M | 0.24% |
+138,966
| New | +$1.51M |
|
55
BioNTech
BNTX
$24.1B
| $1.19M | 0.19% |
+10,000
| New | +$1.19M |
|
56
MoonLake Immunotherapeutics
MLTX
$3.78B
| $1.18M | 0.19% |
23,457
+18,657
| +389% | +$941K |
|
57
enVVeno Medical
NVNO
$15M
| $1.17M | 0.19% |
348,263
+146,535
| +73% | +$492K |
|
58
Vaxcyte
PCVX
$4.17B
| $1.15M | 0.19% |
10,097
-2,153
| -18% | -$246K |
|
59
Disc Medicine
IRON
$2.14B
| $1.11M | 0.18% |
+22,564
| New | +$1.11M |
|
60
Xenon Pharmaceuticals
XENE
$2.99B
| $1.1M | 0.18% |
27,903
+23,203
| +494% | +$914K |
|
61
Beam Therapeutics
BEAM
$1.9B
| $1.08M | 0.17% |
43,900
-28,900
| -40% | -$708K |
|
62
Nuvalent
NUVL
$5.74B
| $1.07M | 0.17% |
+10,442
| New | +$1.07M |
|
63
CytomX Therapeutics
CTMX
$350M
| $1.07M | 0.17% |
903,959
+331,789
| +58% | +$392K |
|
|
AVDL
64
Avadel Pharmaceuticals
AVDL
$1.42B
| $1.06M | 0.17% |
+80,900
| New | +$1.06M |
|
65
iBio
IBIO
$16.9M
| $1.06M | 0.17% |
476,212
-93,788
| -16% | -$208K |
|
66
Pfizer
PFE
$141B
| $1.04M | 0.17% |
35,950
-4,000
| -10% | -$116K |
|
67
Exact Sciences
EXAS
$9.33B
| $1.04M | 0.17% |
15,200
+14,600
| +2,433% | +$995K |
|
68
Kezar Life Sciences
KZR
$28.5M
| $1.03M | 0.17% |
1,338,273
+251,775
| +23% | +$195K |
|
|
BCAX
69
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $1.03M | 0.17% |
+40,440
| New | +$1.03M |
|
70
Astria Therapeutics
ATXS
$394M
| $1.03M | 0.17% |
93,284
-44,874
| -32% | -$494K |
|
71
Eli Lilly
LLY
$661B
| $1.02M | 0.17% |
+1,150
| New | +$1.02M |
|
72
Spero Therapeutics
SPRO
$117M
| $996K | 0.16% |
743,459
-175,470
| -19% | -$235K |
|
|
ITCI
73
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $980K | 0.16% |
+13,400
| New | +$980K |
|
74
Agios Pharmaceuticals
AGIO
$2.36B
| $946K | 0.15% |
+21,300
| New | +$946K |
|
|
RVNC
75
DELISTED
Revance Therapeutics, Inc.
RVNC
| $945K | 0.15% |
+182,166
| New | +$945K |
|